Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Myeloma Induce Fapα+ Macrophage to Remodel Immune Microenvironment Which Lead to Anti-PD-1 Dilemma

Huiyao Gu, Jingsong He, MD, Enfan Zhang, Zhen Cai, MD PhD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-139535

Published: 2020

Journal Articles

Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-134785

Published: 2020

Journal Articles

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Jimin Shi, MD, Liqin Cao, MD, Yi Luo, MD, Yanmin Zhao, MD, Yamin Tan, MD, Jian Yu, MD, Xiaoyu Lai, MD, Yuanyuan Zhu, MD, Yongxian Hu, MD, Jingsong He, MD, Jie Sun, MD, Weiyan Zheng, MD, Guoqing Wei, MD, He Huang

Blood (2019) 134 (Supplement_1): 2668.

https://doi.org/10.1182/blood-2019-127594

Published: 2019

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

Journal Articles

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

Haimeng Yan, Xuanru Lin, MD, Xi Huang, MD, Zhang En Fan, Donghua He, Xu Ruyi, Huiyao Gu, Yi Li, MD, Jingsong He, MD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1781.

https://doi.org/10.1182/blood.V130.Suppl_1.1781.1781

Published: 2017

Journal Articles

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

Xi Huang, Zhang En Fan, Qingxiao Chen, MS, Haimeng Yan, Xu Ruyi, Xinling Liu, Huiyao Gu, Jingsong He, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1787.

https://doi.org/10.1182/blood.V130.Suppl_1.1787.1787

Published: 2017

Journal Articles

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Jingsong He, MD, Qingxiao Chen, MS, Yang Yang, MD, Yi Li, MD, Li Yang, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 5392.

https://doi.org/10.1182/blood.V130.Suppl_1.5392.5392

Published: 2017

Journal Articles

Clinical Outcome Of R-CHOP Or CHOP Regimen For Elderly Patients With Diffuse Large B-Cell Lymphoma In China：A Single Center’s Experience

Yajian Jiang, M.B.B.S., De Zhou, M.D., Wanzhuo Xie, M.D. Ph.D., Jingsong He, MD, PhD, Jimin Shi, M.D., Yi Luo, M.D., Jie Zhang, M.D., Maofang Lin, M.D, Ph.D, Xiujin Ye, M.D., Zhen Cai, M.D., He Huang, MD, PhD

Blood (2013) 122 (21): 5098.

https://doi.org/10.1182/blood.V122.21.5098.5098

Published: 2013

Journal Articles

The Expression Of CD200 As a Prognostic Factor In Newly Diagnosed Multiple Myeloma

Yi Li, M.Med, Wenjun Wu, M.Med, Jingsong He, MD, PhD, Xiaoyan Han, M.Med, Gaofeng Zheng, M.Med, Fuming Zi, M.Med, Li Yang, M.Med, Cai Wu, M.Med, Donghua He, PhD, Yi Zhao, PhD, Yang Yang, PhD, Lijuan Wang, PhD, Xiujin Ye, M.D. Ph.D., He Huang, MD, PhD., Qing Yi, MD, PhD, Zhen Cai, MD, PhD

Blood (2013) 122 (21): 3082.

https://doi.org/10.1182/blood.V122.21.3082.3082

Published: 2013

Journal Articles

Fibroblast Activation Protein Protects Bortezomib Induced Apoptosis In Multiple Myeloma Cells Through β-Catenin Signaling Pathway

Fuming Zi, M.Med, Jingsong He, MD, PhD, Donghua He, PhD, Yi Li, M.Med, Li Yang, M.Med, Lijuan Wang, PhD, Yang Yang, PhD, Yi Zhao, PhD, Wenjun Wu, M.Med, He Huang, MD, PhD., Qing Yi, MD, PhD, Zhen Cai, MD, PhD

Blood (2013) 122 (21): 3083.

https://doi.org/10.1182/blood.V122.21.3083.3083

Published: 2013

Journal Articles

The Choice Of Regimens Based On Bortezomib For Patients With Newly Diagnosed Multiple Myeloma

Li Yang, M.Med, Jingsong He, MD, PhD, Xiaoyan Han, M.Med, Gaofeng Zheng, M.Med, Weiyan Zheng, Ph.D., Guoqing Wei, Ph.D.;M.D., Wenjun Wu, M.Med, Xiujin Ye, M.D. Ph.D., Jimin Shi, M.D., Wanzhuo Xie, M.D. Ph.D., Li Li, M.Med, Jie Zhang, M.Med, Weijia Huang, M.Med, Yi Zhao, PhD, He Huang, MD, PhD., Xuejin Zhang, M.D. Ph.D., Jiaping Fu, M.D. Ph.D., Zhen Cai, MD, PhD

Blood (2013) 122 (21): 1990.

https://doi.org/10.1182/blood.V122.21.1990.1990

Published: 2013

Journal Articles

Homoharringtonine In Combination With Cytarabine and Etoposide For Induction Therapy In Patients With De Novo Acute Myelogenous Leukemia

Jingsong He, MD, PhD, Li Li, M.Med, Jingjing Zhu, Yi Zhao, PhD, Wenjun Wu, M.Med, Yanlong Zheng, Gaofeng Zheng, M.Med, Weiyan Zheng, M.D., Xiaoli Zhu, He Huang, MD, PhD., Xiujin Ye, M.D. Ph.D.

Blood (2013) 122 (21): 5006.

https://doi.org/10.1182/blood.V122.21.5006.5006

Published: 2013

Journal Articles

Prospective Evaluation Of Allo-HSCT From Haploidentical-Related Donors Compared With Matched Sibling Donors and Unrelated Donors For Patients With Hematological Malignancies: Results From An Open-Label Trial

Yi Luo, Haowen Xiao, Xiaoyu Lai, Jimin Shi, Yamin Tan, Jingsong He, MD, PhD, Wanzhuo Xie, M.D. Ph.D., Weiyan Zheng, M.D., Yuanyuan Zhu, Xiujin Ye, M.D. Ph.D., Zhen Cai, MD, Maofang Lin, He Huang

Blood (2013) 122 (21): 3338.

https://doi.org/10.1182/blood.V122.21.3338.3338

Published: 2013

NARROW

Myeloma Induce Fapα+ Macrophage to Remodel Immune Microenvironment Which Lead to Anti-PD-1 Dilemma

Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Clinical Outcome Of R-CHOP Or CHOP Regimen For Elderly Patients With Diffuse Large B-Cell Lymphoma In China：A Single Center’s Experience

The Expression Of CD200 As a Prognostic Factor In Newly Diagnosed Multiple Myeloma

Fibroblast Activation Protein Protects Bortezomib Induced Apoptosis In Multiple Myeloma Cells Through β-Catenin Signaling Pathway

The Choice Of Regimens Based On Bortezomib For Patients With Newly Diagnosed Multiple Myeloma

Homoharringtonine In Combination With Cytarabine and Etoposide For Induction Therapy In Patients With De Novo Acute Myelogenous Leukemia

Prospective Evaluation Of Allo-HSCT From Haploidentical-Related Donors Compared With Matched Sibling Donors and Unrelated Donors For Patients With Hematological Malignancies: Results From An Open-Label Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only